公开(公告)号：US12270813B2

公开(公告)日：2025-04-08

申请号：US16620459

申请日：2018-06-01

Applicant: BioNTech SE

Inventor： Ugur Sahin

IPC: G01N33/68 ,  A61K39/00

Abstract: The present invention relates to methods for predicting whether peptides or polypeptides comprising disease specific amino acid modifications, in particular tumor-associated neo-antigens, comprise epitopes, in particular tumor-associated neo-epitopes, which are useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

公开(公告)号：US20250101499A1

公开(公告)日：2025-03-27

申请号：US18730527

申请日：2023-01-19

Applicant: BioNTech SE ,  Rheinische Friedrich-Wilhelms-Universität Bonn

Inventor： Irena VLATKOVIC ,  Katalin KARIKO ,  Janos LUDWIG

IPC: C12Q1/6823 ,  C12Q1/6837

Abstract: The present invention relates to a method for analyzing the structure of 5′ terminus of an RNA molecule in a population of RNA molecules using catalytic nucleic acids, e.g., for determining the presence or absence of a 5′ cap structure.

公开(公告)号：US20250025505A1

公开(公告)日：2025-01-23

申请号：US18717782

申请日：2022-12-08

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Petra OEHM ,  Benjamin RENGSTL ,  Katharina REINHARD ,  Liane Monika PREUSSNER ,  Özlem TÜRECI

IPC: A61K35/17 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7105 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783

Abstract: The present disclosure relates to chimeric antigen receptor (CAR) expressing immune effector cells showing highly specific and sensitive recognition of CLDN6 expressing cancer cells as well as a high potential for treating cancer in humans.

公开(公告)号：US12186387B2

公开(公告)日：2025-01-07

申请号：US18071499

申请日：2022-11-29

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Asaf Poran ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin

IPC: A61K39/215 ,  A61K9/127 ,  A61K39/145 ,  A61K45/06 ,  A61K47/26 ,  C12N15/86 ,  A61K39/00

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20240417418A1

公开(公告)日：2024-12-19

申请号：US18702855

申请日：2022-10-21

Applicant: BioNTech SE ,  Consejo Superior de Investigaciones Científicas

Inventor： Jorge Moreno Herrero ,  Heinrich Haas ,  Stephanie Erbar ,  José Manuel García Fernández ,  Juan Manuel Benito Hernández ,  Jose Lopez Fernandez ,  Práxedes Sánchez Mellado

IPC: C07H15/04 ,  A61K9/00 ,  A61K31/7105 ,  A61K47/54 ,  C07H1/00

Abstract: The present disclosure provides compounds, compositions, and complexes useful for delivery of certain agents, including, for example, nucleic acids.

公开(公告)号：US20240415946A1

公开(公告)日：2024-12-19

申请号：US18699937

申请日：2022-10-10

Applicant: BIONTECH SE ,  TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBE

Inventor： Ugur SAHIN ,  David WEBER ,  Carina WALTER ,  Diana BAREA ROLDÁN ,  Ruprecht KUNER ,  Melanie HEIN ,  Martin SUCHAN, ,  Vetena KISSLER ,  Lena Mareen KRANZ

IPC: A61K39/00 ,  A61K9/00 ,  A61K9/127 ,  A61P35/00

Abstract: This disclosure relates to the field of RNA to treat lung cancer, in particular non-small-cell lung carcinoma (NSCLC). Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treatment of lung cancers. Administration of therapeutic RNAs to a patient having lung cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.

公开(公告)号：US20240415828A1

公开(公告)日：2024-12-19

申请号：US18704537

申请日：2022-11-09

Applicant: BIONTECH SE

Inventor： Ugur SAHIN ,  Hariz Iskandar Bin HASSAN ,  Stefan STROBL ,  Roman RÖSEMANN

IPC: A61K31/4745 ,  A61K9/00 ,  A61K31/555 ,  A61K31/7048 ,  A61K39/00 ,  A61P35/00 ,  C07D471/04 ,  C07K16/28

Abstract: The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.

公开(公告)号：US20240408032A1

公开(公告)日：2024-12-12

申请号：US18689727

申请日：2022-09-09

Applicant: BioNTech SE

Inventor： Hossam HEFESHA ,  Heinrich HAAS ,  Ferdia BATES ,  Christian HOTZ ,  Katalin KARIKÓ

IPC: A61K9/51 ,  A61K9/00 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21

Abstract: The present disclosure relates to RNA particles comprising phospholipids with a phosphatidylserine head group for delivering RNA to target tissues after administration, in particular after parenteral, intratumoral, or peritumoral administration, and compositions comprising such RNA particles. The present disclosure also relates to methods for preparing RNA particles described herein.

公开(公告)号：US12153041B2

公开(公告)日：2024-11-26

申请号：US16301019

申请日：2017-05-10

Applicant: BioNTech SE ,  Tron-Translationale Onkologie an der Universitätsmedizin Der Johannesgutenberg-Universität Mainz

Inventor： Mathias Vormehr ,  Ugur Sahin ,  Barbara Schrörs ,  Martin Löwer ,  Sebastian Boegel

IPC: G01N33/50 ,  A61P35/04 ,  G01N33/53 ,  G01N33/68

Abstract: The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

公开(公告)号：US20240383947A1

公开(公告)日：2024-11-21

申请号：US18287608

申请日：2022-04-20

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alexander Muik

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/215 ,  A61K39/295 ,  A61P37/04

Abstract: This disclosure relates to the field of preventing or treating virus infection, in particular, the disclosure relates to agents for vaccination against virus infection and inducing effective virus antigen-specific immune responses such as antibody and/or T cell responses and methods for generating and using such agents. Administration of agents such as RNA disclosed herein to a subject can protect the subject against virus infection. Specifically, the present disclosure relates to amino acid sequences comprising at least a portion of a virus protein having amino acid modifications found in other variants of the virus protein. Administration of RNA encoding one or more of the amino acid sequences may provide protection against diverse virus variants. Methods and agents described herein are, in particular, useful for the prevention or treatment of coronavirus infection such as SARS-CoV-2 infection.